In this article, we will look at the 8 Best Stem Cell Therapy Stocks to Buy.
On April 23, Bankim Chadha, chief global strategist at Deutsche Bank, appeared on CNBC’s ‘Money Movers’ to talk about uncertainty in the markets and what to expect with the earnings season.
He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly and historically around geopolitical events and risks. While there are some twists and turns this time, we have almost exactly followed the average or typical behavior of the market, which is a sharp selloff three weeks down 6-8%. He further stated that the surprising thing for most people is that the market tends to recover completely in another three weeks.
READ ALSO: 8 Best Low Priced Stocks to Buy Right Now AND 8 Best Bitcoin Stocks to Buy Now.
Chadha was of the view that if the equity market is doing what it always does, it is hard to say that it is getting optimistic or constructive. In his outlook, he expects the Fed to remain on hold near neutral through the remainder of 2026, and sees WTI crude averaging $90 a barrel in fiscal Q2, and falling gradually. He is not forecasting a recession, but a low-hiring, low-firing labor market remains a risk. Overall, Chadha believes that there is still a lot of upside in the markets.
With these broader market trends in view, let’s look at the best stem cell therapy stocks to buy now.
Our Methodology
We used stock screeners to compile a list of stocks involved with stem cell therapy and chose the top 8 with the highest number of hedge fund holders as of Q4 2025, sourcing the hedge fund sentiment data from Insider Monkey’s database. The list is sorted in ascending order of hedge fund sentiment.
Note: All data was recorded on April 23.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8 Best Stem Cell Therapy Stocks to Buy
8. Sanofi (NASDAQ:SNY)
Sanofi (NASDAQ:SNY) is one of the best stem cell therapy stocks to buy. Sanofi (NASDAQ:SNY) announced financial results for fiscal Q1 2026 on April 23, reporting double-digit sales and business EPS growth. Fiscal Q1 sales growth was 13.6% at CER, while business earnings per share reached €1.88. Pharma launches sales rose by 49.6% and reached €1.2 billion, driven primarily by Ayvakit, ALTUVIIIO, and Sarclisa.
Management further reported that Dupixent sales grew by 30.8% to €4.2 billion, suggesting a solid start to 2026. Similarly, vaccine sales grew by 2.1% to €1.3 billion, benefiting from Heplisav-B. Sanofi also announced that Research and Development expenses reached €1.7 billion, up by 1.5%, while selling and general expenses reached €2.3 billion, up by 11.6%, primarily due to the effect of recent acquisitions.
The company also provided insights into its pipeline progress, with five regulatory approvals, all in immunology, and positive pipeline readouts, including venglustat in the rare disease GD3 (phase 3) and lunsekimig in respiratory diseases (phase 2). Sanofi also reported two regulatory submission acceptances, one phase 3 study start, and four regulatory designations (breakthrough, orphan).
Sanofi researches, produces, and distributes pharmaceutical products. The company’s operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.
7. AstraZeneca PLC (NYSE:AZN)
AstraZeneca PLC (NYSE:AZN) is one of the best stem cell therapy stocks to buy. AstraZeneca PLC (NYSE:AZN) announced on April 21 that positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris met its primary endpoint, exhibiting a statistically significant and clinically meaningful reduction of proteinuria. This was based on a 24-hour urine protein creatinine ratio at week 34 in adults with immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Management stated that the primary endpoint of change from baseline in estimated glomerular filtration rate (eGFR) will be measured at week 106.
AstraZeneca PLC also reported that the safety profile observed in the trial remained consistent with the known profile of Ultomiris, with no new safety concerns identified. According to the management, the company will seek accelerated approval in key markets and will present these results at a forthcoming medical meeting. IgAN is a rare, inflammatory disease of the kidneys that can result in chronic kidney disease (CKD) and progress to end-stage kidney disease (ESKD).
AstraZeneca PLC is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca PLC distributes its products and services through local representative offices and distributors.
6. Biogen Inc. (NASDAQ:BIIB)
Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was upgraded to Buy from Neutral by UBS, with the firm adjusting the price target on the stock to $225 from $185. It told investors in a research note that it has increased conviction on the company’s pipeline catalysts coming over the next 12-15 months, adding that the readouts should move the stock higher going into 2027.
UBS also stated that it sees upside on the BIIB080 tau data this summer, adding that the “real upside catalyst” in fiscal Q4 is the Phase III litifilimab data in systemic lupus. It contended that Biogen Inc. offers a “window of pipeline catalysts” and is an “under-owned out-of- favor stock that trades at a discount to large-cap peers”.
In a separate development, Wells Fargo upgraded Biogen Inc. to Overweight from Equal Weight on April 20, lifting the price target on the stock to $250 from $200.
Biogen Inc. is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases worldwide. Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
5. Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc. (NASDAQ:AMGN) with a Hold rating on April 21, setting a price target of $366. The firm told investors in a research note that the company has executed well on its key growth drivers, but this is reflected in the stock’s good performance since last October. It further stated that it believes Amgen Inc.’s current valuation to be appropriate, adding that meaningful appreciation from here “could be more challenging” because of some loss of exclusivities and pricing pressure across several of its large mature products.
For additional perspective, in its fiscal Q4 and full year 2025 results, Amgen Inc. reported strong performance in the full year with double-digit growth in revenues and EPS. Total revenues for fiscal Q4 rose 9% to $9.9 billion compared to the prior year period, with product sales growing 7%, driven by 10% volume growth. Total revenues for the full year reached $36.8 billion, up 10% compared to the same quarter last year.
Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.
4. Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stem cell therapy stocks to buy. Gilead Sciences, Inc. (NASDAQ:GILD) announced on April 17 the attainment of all required regulatory approvals for its previously announced acquisition of Arcellx. The company also stated that it has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.
In a separate development, Gilead Sciences, Inc. received a rating update from Truist on April 8, with the firm lifting the price target on the stock to $155 from $152 while reaffirming a Buy rating on the shares. The rating update came as part of a broader research note previewing fiscal Q1 earnings in Biotech, with the firm stating that reactivity to regulatory and policy shifts across the sector is continuing to ease.
Truist also noted a recent pickup in deal activity, which it believes holds the potential to build momentum through the remainder of the year into midterms. The firm further told investors in a research note that for Gilead Sciences, Inc., it is looking for its management commentary on Yeztugo launch strategy and payer access dynamics in the U.S./EU markets, along with any anito-cel launch preparation updates ahead of the December 23, 2026, PDUFA.
Gilead Sciences, Inc. is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs, and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others.
3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best stem cell therapy stocks to buy. TD Cowen lifted the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $960 from $880 on April 23, reaffirming a Buy rating on the shares. The firm updated its model ahead of the fiscal Q1 results, and slightly decreased Eylea and Libtayo estimates and increased Dupi estimate, while bringing the non-GAAP EPS estimate for fiscal Q1 up to $9.30.
The rating update came the same day Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Otarmeni™, which is the first gene therapy and second new molecular entity approved under the FDA Commissioner’s National Priority Voucher program.
Management reported that Otarmeni is an “adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear”. Formerly known as DB-OTO, Otarmeni is the first and only in vivo gene therapy for OTOF-related hearing loss, and will be made available by Regeneron Pharmaceuticals, Inc. for free in the United States.
Regeneron Pharmaceuticals, Inc. is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.
2. AbbVie Inc. (NYSE:ABBV)
AbbVie Inc. (NYSE:ABBV) is one of the best stem cell therapy stocks to buy. On April 23, Piper Sandler cut the price target on AbbVie Inc. (NYSE:ABBV) to $294 from $299 while reaffirming an Overweight rating on the shares. The rating update came ahead of the quarterly results, with the firm saying that the company has become a bit controversial. Despite that, Piper is making a case for why there is no need for investors to worry, as the primary worry on AbbVie Inc., as seen by the firm, is driven in part by the rollout of oral IL-23-directed treatment Icotyde by Johnson & Johnson in the psoriasis setting, along with how it could impact the trajectory of Skyrizi.
The firm would anticipate that Icotyde will likely expand the overall footprint of the IL-23 category, adding that Skyrizi penetration in inflammatory bowel disease is still quite low. It also stated that although the consensus estimates on Skyrizi may have caught up with its growth trajectory, there are other parts of the business where that is not the case.
AbbVie Inc. is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
1. Thermo Fisher Scientific Inc. (NYSE:TMO)
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best stem cell therapy stocks to buy. On April 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced financial results for fiscal Q1 2026. Revenue for the quarter rose 6% to $11.01 billion, compared to $10.36 billion in the same quarter last year. Organic revenue underwent a 1% growth. Management further reported that the GAAP diluted EPS in fiscal Q1 2026 was $4.43, reflecting an 11% growth compared to the prior year period. GAAP operating income for the quarter reached $1.86 billion, up 9% versus the year-ago quarter, while GAAP operating margin was 16.9%, compared with 16.6% in fiscal Q1 2025.
Thermo Fisher Scientific Inc. also stated that it advanced its proven growth strategy, launching a range of high-impact and innovative products during the quarter. This included a Thermo Scientific™ Glacios™ 3 Cryo-TEM, the Thermo Scientific™ TSQ Certis™ triple quadrupole mass spectrometer, the Thermo Scientific™ Niton™ XL5e Handheld XRF Analyzer, and the Gibco™ CTS™ Compleo™ Fill and Finish System.
Thermo Fisher Scientific Inc. provides analytical instruments, reagents, equipment, software, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Hedge Fund Resource Center